Sanofi Sa Stock Cash Flow From Operations
| SAN Stock | EUR 101.46 2.26 2.18% |
Sanofi SA fundamentals help investors to digest information that contributes to Sanofi SA's financial success or failures. It also enables traders to predict the movement of Sanofi Stock. The fundamental analysis module provides a way to measure Sanofi SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi SA stock.
Sanofi |
Sanofi SA Company Cash Flow From Operations Analysis
Sanofi SA's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Sanofi SA Cash Flow From Operations | 10.53 B |
Most of Sanofi SA's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Sanofi SA has 10.53 B in Cash Flow From Operations. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The cash flow from operations for all France stocks is significantly lower than that of the firm.
Sanofi Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi SA's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi SA could also be used in its relative valuation, which is a method of valuing Sanofi SA by comparing valuation metrics of similar companies.Sanofi SA is currently under evaluation in cash flow from operations category among its peers.
Sanofi Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0559 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.24 % | |||
| Current Valuation | 128.44 B | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Insiders | 11.23 % | |||
| Shares Owned By Institutions | 47.20 % | |||
| Price To Earning | 8.63 X | |||
| Price To Book | 1.61 X | |||
| Price To Sales | 2.53 X | |||
| Revenue | 45.39 B | |||
| Gross Profit | 31.7 B | |||
| EBITDA | 13.77 B | |||
| Net Income | 8.37 B | |||
| Cash And Equivalents | 9.72 B | |||
| Cash Per Share | 7.76 X | |||
| Total Debt | 14.86 B | |||
| Debt To Equity | 0.34 % | |||
| Current Ratio | 1.55 X | |||
| Book Value Per Share | 59.70 X | |||
| Cash Flow From Operations | 10.53 B | |||
| Earnings Per Share | 6.66 X | |||
| Price To Earnings To Growth | 1.63 X | |||
| Target Price | 103.6 | |||
| Number Of Employees | 91.57 K | |||
| Beta | 0.41 | |||
| Market Capitalization | 110.83 B | |||
| Total Asset | 124.58 B | |||
| Z Score | 4.2 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.86 % | |||
| Net Asset | 124.58 B | |||
| Last Dividend Paid | 3.56 |
About Sanofi SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Sanofi Stock
Sanofi SA financial ratios help investors to determine whether Sanofi Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sanofi with respect to the benefits of owning Sanofi SA security.